Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination drug is a bowel cleansing regimen used primarily for colorectal cancer screening procedures such as sigmoidoscopy and colonoscopy. It consists of an oral component (Pico-Salax) and a rectal component (sodium phosphate enema). Sodium picosulfate is a stimulant laxative that is metabolized by colonic bacteria into an active metabolite, which stimulates peristalsis. Magnesium oxide and citric acid react in water to form magnesium citrate, an osmotic laxative that draws water into the bowel lumen. Sodium phosphate, administered rectally, acts as an additional osmotic agent to clear the distal colon. Together, these agents ensure thorough evacuation of the bowel to allow for clear visualization during endoscopic examination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium picosulfate + magnesium oxide + citric acid + sodium phosphate.